4 лекарствени продукти, които повлияват ентерохепаталния кръговрат, поради потенциалното намаление на ефикасността на Mycophenolate mofetil Teva.
In view of the significant reduction in the AUC (area under the curve) of MPA by cholestyramine, caution should be used in the concomitant administration of Mycophenolate mofetil Teva with medicinal products that interfere with enterohepatic recirculation because of the potential to reduce the efficacy of Mycophenolate mofetil Teva.